Literature DB >> 22985129

Prospective comparison of clinical prognostic scores in elder patients with a pulmonary embolism.

D Zwierzina1, A Limacher, M Méan, M Righini, K Jaeger, H-J Beer, B Frauchiger, J Osterwalder, N Kucher, C M Matter, M Banyai, A Angelillo-Scherrer, B Lämmle, M Egloff, M Aschwanden, L Mazzolai, O Hugli, M Husmann, H Bounameaux, J Cornuz, N Rodondi, D Aujesky.   

Abstract

BACKGROUND: The Geneva Prognostic Score (GPS), the Pulmonary Embolism Severity Index (PESI) and its simplified version (sPESI) are well-known clinical prognostic scores for a pulmonary embolism (PE).
OBJECTIVES: To compare the prognostic performance of these scores in elderly patients with a PE. PATIENTS AND METHODS: In a multicenter Swiss cohort of elderly patients with venous thromboembolism, we prospectively studied 449 patients aged ≥ 65 years with a symptomatic PE. The outcome was 30-day overall mortality. We dichotomized patients as low vs. higher risk in all three scores using the following thresholds: GPS scores ≤ 2 vs. > 2, PESI risk classes I-II vs. III-V and sPESI scores 0 vs. ≥ 1. We compared 30-day mortality in low- vs. higher-risk patients and the areas under the receiver-operating characteristic curve (ROC).
RESULTS: Overall, 3.8% of patients (17/449) died within 30 days. The GPS classified a greater proportion of patients as low risk (92% [413/449]) than the PESI (36.3% [163/449]) and the sPESI (39.6% [178/449]) (P < 0.001 for each comparison). Low-risk patients based on the sPESI had a mortality of 0% (95% confidence interval [CI] 0-2.1%) compared with 0.6% (95% CI 0-3.4%) for low-risk patients based on the PESI and 3.4% (95% CI 1.9-5.6%) for low-risk patients based on the GPS. The areas under the ROC curves were 0.77 (95% CI 0.72-0.81), 0.76 (95% CI 0.72-0.80) and 0.71 (95% CI 0.66-0.75), respectively (P = 0.47).
CONCLUSIONS: In this cohort of elderly patients with PE, the GPS identified a higher proportion of patients as low risk but the PESI and sPESI were more accurate in predicting mortality.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  elderly patients; prognostic scores; pulmonary embolism

Mesh:

Year:  2012        PMID: 22985129     DOI: 10.1111/j.1538-7836.2012.04929.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

1.  Mortality at 30 and 90 days in elderly patients with pulmonary embolism: a retrospective cohort study.

Authors:  Hernan Polo Friz; Mauro Molteni; Davide Del Sorbo; Lorenzo Pasciuti; Matteo Crippa; Giulia Villa; Dario Francesco Meloni; Laura Primitz; Andrea Galli; Magda Rognoni; Luca Cavalieri d'Oro; Guido Arpaia; Claudio Cimminiello
Journal:  Intern Emerg Med       Date:  2014-12-25       Impact factor: 3.397

2.  Comorbidity assessment as predictor of short and long-term mortality in elderly patients with hemodynamically stable acute pulmonary embolism.

Authors:  Hernan Polo Friz; Valeria Corno; Annalisa Orenti; Chiara Buzzini; Chiara Crivellari; Francesco Petri; Melisa Polo Friz; Veronica Punzi; Daniela Teruzzi; Luca Cavalieri d'Oro; Cristina Giannattasio; Giuseppe Vighi; Claudio Cimminiello; Patrizia Boracchi
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

3.  Home treatment of patients with small to medium sized acute pulmonary embolism.

Authors:  J E Elf; J Jögi; M Bajc
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

4.  Comparison of Cardiac and Non-Cardiac Biomarkers for Risk Stratification in Elderly Patients with Non-Massive Pulmonary Embolism.

Authors:  Nicolas Vuilleumier; Aurélien Simona; Marie Méan; Andreas Limacher; Pierre Lescuyer; Eric Gerstel; Henri Bounameaux; Drahomir Aujesky; Marc Righini
Journal:  PLoS One       Date:  2016-05-24       Impact factor: 3.240

5.  Comparing three clinical prediction rules for primarily predicting the 30-day mortality of patients with pulmonary embolism: The "Simplified Revised Geneva Score," the "Original PESI," and the "Simplified PESI".

Authors:  Babak Tamizifar; Farid Fereyduni; Morteza Abdar Esfahani; Saeed Kheyri
Journal:  Adv Biomed Res       Date:  2016-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.